Ferrone et al evaluated prognostic factors in patients with a pancreatic endocrine tumors. These can help identify patients who may benefit from more aggressive management. The authors are from Memorial Sloan-Kettering Cancer Center.
Outcome: 5 year disease-specific survival (DSS)
Parameters:
(1) histologic grade
(2) diameter in cm
(3) presence or absence of nodal or distant metastases
Histologic grade:
(1) no necrosis AND 0-1 mitoses in 50 high power fields (40x objective) = benign (low grade)
(2) necrosis OR >= 2 mitoses in 50 high power fields = intermediate
Histologic Grade |
Distant Metastases |
Diameter |
Percent 5 Year Disease Specific Survival (DSS) |
low |
present |
NA |
93% |
low |
absent |
>= 2 cm |
87% |
low |
absent |
< 2 cm |
100% |
intermediate |
present |
NA |
58% |
intermediate |
absent |
>= 2 cm |
72% |
intermediate |
absent |
< 2 cm |
100% |
where:
• In the WHO classification metastases indicate a malignant tumor.
• The differential diagnosis of metastasis (especially for a low grade histology) is a multifocal tumor.
Specialty: Hematology Oncology, Surgery, general, Endocrinology
ICD-10: ,